ProMIS Neurosciences Inc. Files 2023 Annual Report on Form 10-K

Ticker: PMN · Form: 10-K · Filed: Apr 1, 2024

Sentiment: neutral

Topics: 10-K, ProMIS Neurosciences, Financial Report, Warrants, Pharmaceuticals

TL;DR

<b>ProMIS Neurosciences Inc. has filed its 2023 annual report (10-K), detailing financial instruments and corporate history.</b>

AI Summary

ProMIS Neurosciences Inc. (PMN) filed a Annual Report (10-K) with the SEC on April 1, 2024. ProMIS Neurosciences Inc. filed its 2023 Form 10-K on April 1, 2024. The company's fiscal year ends on December 31st. The filing includes data related to warrants issued in August 2023. Key financial metrics such as Gain/Loss from Change in Fair Value of Financial Instruments are detailed. The company was formerly known as AMORFIX LIFE SCIENCES LTD until August 31, 2006.

Why It Matters

For investors and stakeholders tracking ProMIS Neurosciences Inc., this filing contains several important signals. This filing provides a comprehensive overview of ProMIS Neurosciences' financial performance and position for the fiscal year 2023, crucial for investors to assess the company's health and future prospects. The inclusion of specific data points on warrants and financial instruments offers insights into the company's capital structure and potential liabilities or equity dilution.

Risk Assessment

Risk Level: medium — ProMIS Neurosciences Inc. shows moderate risk based on this filing. The company operates in the pharmaceutical preparations sector, which is subject to significant regulatory hurdles, lengthy development cycles, and high R&D costs, as indicated by its SIC code and the nature of its business.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's financial health and operational risks.

Key Numbers

Key Players & Entities

FAQ

When did ProMIS Neurosciences Inc. file this 10-K?

ProMIS Neurosciences Inc. filed this Annual Report (10-K) with the SEC on April 1, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by ProMIS Neurosciences Inc. (PMN).

Where can I read the original 10-K filing from ProMIS Neurosciences Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ProMIS Neurosciences Inc..

What are the key takeaways from ProMIS Neurosciences Inc.'s 10-K?

ProMIS Neurosciences Inc. filed this 10-K on April 1, 2024. Key takeaways: ProMIS Neurosciences Inc. filed its 2023 Form 10-K on April 1, 2024.. The company's fiscal year ends on December 31st.. The filing includes data related to warrants issued in August 2023..

Is ProMIS Neurosciences Inc. a risky investment based on this filing?

Based on this 10-K, ProMIS Neurosciences Inc. presents a moderate-risk profile. The company operates in the pharmaceutical preparations sector, which is subject to significant regulatory hurdles, lengthy development cycles, and high R&D costs, as indicated by its SIC code and the nature of its business.

What should investors do after reading ProMIS Neurosciences Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's financial health and operational risks. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,429 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2024-04-01 16:21:07

Key Financial Figures

Filing Documents

Business

Item 1. Business 7

Risk Factors

Item 1A. Risk Factors 46

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 95

Cybersecurity

Item 1C. Cybersecurity 95

Properties

Item 2. Properties 96

Legal Proceedings

Item 3. Legal Proceedings 96

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 96 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 96

Reserved

Item 6. Reserved 98

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 99

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 106

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data F-1

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 100

Controls and Procedures

Item 9A. Controls and Procedures 100

Other Information

Item 9B. Other Information 101

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 101 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 101

Executive Compensation

Item 11. Executive Compensation 102

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 102

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 102

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 102 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 102

Form 10-K Summary

Item 16. Form 10-K Summary 102

Signatures

Signatures 108 Index to Consolidated Financial Statements F-1 2 Table of Contents SUMMARY OF THE MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks are described more fully in Item 1A – "Risk Factors" and include, but are not limited to, the following: Risks Related to the Development of Our Product Candidates Our product candidates are still in the early stages of development and there is significant uncertainty that any such products will actually be developed. We have concentrated a portion of our research and development efforts on the treatment of AD, a field that has seen very limited success in drug development. Our business is heavily dependent on the successful development, regulatory approval and commercialization of PMN310 and any future product candidates that we may develop or acquire, including PMN442 and PMN267. Nonclinical and clinical drug development involves a lengthy, expensive and uncertain process. The results of nonclinical studies and early clinical trials are not always predictive of future results. PMN310 or any other product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. Interim, "top-line" and preliminary results from our clinical trials that we announce or publish from time to time may change as more data become available and is subject to audit and verification procedures that could result in material changes in the final data. We cannot be certain that PMN310, PMN442, PMN267 or any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market our product candidates. Risks Related to the Commercialization of Our Product Candidates The market opportunities for PMN310, PMN442, PMN267, and future product ca

Business

Item 1. Business Overview ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, progressive supranuclear palsy, corticobasal degeneration (respectively, AD, MSA, ALS, FTLD, PSP, CBD) and schizophrenia. A common biologic cause contributes to each of these conditions, in that certain proteins, which normally perform a needed function, when misfolded, can cause neuronal degeneration and death, contributing to morbidity and mortality. ProMIS' technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics. ProMIS' Platform Technology ProMIS' scientific foundation is centered on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. Genetic and experimental research in the neuroscience community has demonstrated that propagating, neurotoxic, misfolded proteins (also referred to as prion-like particles or toxic soluble oligomers) are fundamental drivers of multiple neurodegenerative diseases, including AD, MSA, and ALS. ProMIS' platform technology allows for the identification of conformational epitopes that become exposed on toxic, misfolded forms of a given protein but are not present on the properly folded form of the same protein. Such disease-specific epitopes (DSEs) can then be used to generate therapeutic antibody candidates that selectively target toxic forms of the protein without interfering with essential functions of the healthy protein. The ability to model prot

View on Read The Filing